Human osteocalcin: A strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer

Journal of Gene Medicine

Volumn 9, Issue 6, 2007, Pages 511-520

  McCarthy, Helen O ^a   Coulter, Jonathan A ^a   Worthington, Jenny ^b   Robson, Tracy ^a   Hirst, David G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Gene therapy; Hormone refractory prostate cancer; iNOS; Osteocalcin; Transcriptional targeting

Indexed keywords

ANDROGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; OSTEOCALCIN;

ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CELL SPECIFICITY; CELL STRAIN LNCAP; CELL SURVIVAL; CLONOGENIC ASSAY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; MICROVASCULATURE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; TARGET CELL; TRANSGENE; VASCULAR ENDOTHELIUM;

CELL DEATH; CELL LINE, TUMOR; CYTOMEGALOVIRUS; GENE THERAPY; GREEN FLUORESCENT PROTEINS; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; OSTEOCALCIN; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; TRANSFECTION;

EID: 34347225612     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1045     Document Type: Article

References (59)

1. Kaliberov SA, Buchsbaum DJ. Gene delivery and gene therapy of prostate cancer. Expert Opin Drug Deliv 2006; 3: 37-51.
2. http://www.cancerresearchuk.org.
3. Eisenberger MA, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-1042.
4. Muthuramalingam SR, Patel K, Protheroe A. Management of patients with hormone refractory prostate cancer. Clin Oncol (R Coll Radiol) 2004; 16: 505-516.
5. Petrylak DP. Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol 2002; 20: 31-35.
6. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
7. Patel P, Ashdown D, James N. Is gene therapy the answer for prostate cancer? Prostate Cancer Prostatic Dis 2004; 7: S14-19.
8. Satoh T, et al. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 2004; 59: 562-571.
9. Eder IE, Haag P, Bartsch G, Klocker H. Gene therapy strategies in prostate cancer. Curr Gene Ther 2005; 5: 1-10.
10. Foley R, Lawler M, Hollywood D. Gene-based therapy in prostate cancer. Lancet Oncol 2004; 5: 469-479.
11. Koeneman KS, Hsieh JT. The prospect of gene therapy for prostate cancer: update on theory and status. Curr Opin Urol 2001; 11: 489-494.
12. http://www.abedia.com/wiley/countries.php.
13. Maitland NJ, Stanbridge LA, Dussupt V. Targeting gene therapy for prostate cancer. Curr Pharm Des 2004; 10: 531-555.
14. Ast G. Drug-targeting strategies for prostate cancer. Curr Pharm Des 2003; 9: 455-466.
15. Latham LIP, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector. Cancer Res 2000; 60: 334-341.
16. Pang S. Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene. Cancer Gene Ther 2000; 7: 991-996.
17. Ikegami S, et al. Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition. Jpn J Cancer Res 2002; 93: 1154-1163.
18. Ficazzola MA, Taneja SS. Prospects for gene therapy in human prostate cancer. Mol Med Today 1998; 4: 494-504.
19. Price PA. Vitamin K-dependent formation of bone Gla protein (osteocalcin) and its function. Vitam Horm 1985; 42: 65-108.
20. Koeneman KS, et al. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 2000; 18: 102-110.
21. Curatolo C, et al. Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase. Eur Urol 1992; 21 Suppl 1): 105-107.
22. Brown B, Laorr A, Greenspan A, Stadalnik R. Negative bone scintigraphy with diffuse osteoblastic breast carcinoma metastases. Clin Nucl Med 1994; 19: 194-196.
23. Dodds RA, et al. Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: An in vitro and ex vivo study of remodeling bone. J Bone Miner Res 1995; 10: 1666-1680.
24. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999; 39: 246-261.
25. Stein GS, Lian JB, Owen TA. Bone cell differentiation: A functionally coupled relationship between expression of cell-growth- and tissue-specific genes. Curr Opin Cell Biol 1990; 2: 1018-1027.
26. Kondo H, Ohyama T, Ohya K, Kasugai S. Temporal changes of mRNA expression of matrix proteins and parathyroid hormone and parathyroid hormone-related protein (PTH/PTHrP) receptor in bone development. J Bone Miner Res 1997; 12: 2089-2097.
27. Huang WC, et al. Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: Role of cAMP-dependent protein kinase A signaling pathway. Cancer Res 2005; 65: 2303-2313.
28. Yeung F, et al. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem 2002; 277: 2468-2476.
29. Kubo H, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003; 14: 227-241.
30. Hinata N, et al. Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University. Int J Urol 2006; 13: 834-837.
31. Shirakawa T, et al. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy. Cancer Gene Ther 1998; 5: 274-280.
32. Matsubara S, et al. A conditional replication-competent adenoviral vector, Ad-OC-Ela, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 2001; 61: 6012-6019.
33. Kim PK, Zamora R, Petrosko P, Billiar TR. The regulatory role of nitric oxide in apoptosis. Int Immunopharmacol 2001; 1: 1421-1441.
34. Porasuphatana S, Tsai P, Rosen GM. The generation of free radicals by nitric oxide synthase. Comp Biochem Physiol C Toxicol Pharmacol 2003; 134: 281-289.
35. Wang Z, et al. Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity. Cancer Res 2004; 64: 1386-1395.
36. Worthington J, Robson T, O'Keeffe M, Hirst DG. Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: A novel suicide gene therapy. Gene Ther 2002; 9: 263-269.
37. Worthington J, et al. use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J Gene Med 2004; 6: 673-680.
38. Worthington J, Robson T, Scott S, Hirst D. Evaluation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancer. Gene Ther 2005; 12: 1417-1423.
39. Worthington J, et al. Modification of vascular tone using iNOS under the control of a radiation-inducible promoter. Gene Ther 2000; 7: 1126-1131.
40. McCarthy HO, et al. p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther 2007; 14: 246-255.
41. Jones MK, Tsugawa K, Tarnawski AS, Baatar D. Dual actions of nitric oxide on angiogenesis: Possible roles of PKC, ERK, and AP-1. Biochem Biophys Res Commun 2004; 318: 520-528.
42. Wei D, et al. Direct demonstration of negative regulation of tumor growth and metastasis by host-inducible nitric oxide synthase. Cancer Res 2003; 63: 3855-3859.
43. Le X, Wei D, Huang S, Lancaster JR Jr, Xie K. Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors. Proc Natl Acad Sci U S A 2005; 102: 8758-8763.
44. Kurimoto M, et al. Growth inhibition and radiosensitization of cultured glioma cells by nitric oxide generating agents. J. Neurooncol 1999; 42: 35-44.
45. Cook T, et al. Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res 2004; 64: 8015-8021.
46. Soler MN, et al. Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase II DNA injection. J Gene Med 2000; 2: 344-352.
47. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747-754.
48. Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 2006; 4 CD006250.
49. Mike S, et al. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 2006; 4: CD005247.
50. Visakorpi T, et al. Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: Implications for prognosis and response to endocrine therapy. Br J Cancer 1991; 64: 578-582.
51. Kallioniemi OP, et al. Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. Cytometry 1991; 12: 413-421.
52. Robson T, Hirst D. Transcriptional targeting in cancer gene therapy. J Biomed Biotechnol 2003; 2: 110-137.
53. Wink DA, et al. Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin. Nitric Oxide 1997; 1: 88-94.
54. Azizzadeh B, et al. Nitric oxide improves cisplatin cytotoxicity in head and neck squamous cell carcinoma. Laryngoscope 2001; 111: 1896-1900.
55. Liu J, et al. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation. Mol Cancer Ther 2004; 3: 709-714.
56. Bratasz A, et al. Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. Proc Natl Acad Sci U S A 2006; 103: 3914-3919.
57. Konovalova NP, Goncharova SA, Volkova LM, Rajewskaya TA, Eremenko LT, Korolev AM. Nitric oxide donor increases the efficiency of cytostatic therapy and retards the development of drug resistance. Nitric Oxide 2003; 8: 59-64.
58. Leonetti C, et al. Efficacy of a nitric oxide-releasing non-steroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. Mol Cancer Ther 2006; 5: 919-926.
59. Jia L, Schweizer J, Wang Y, Cerna C, Wong H, Revilla M. Effect of nitric oxide on cytotoxicity of Taxol: Enhanced Taxol transcellular permeability. Biochem Pharmacol 2003; 6: 2193-2199.